## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($56.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Bio-Techne (NASDAQ: TECH) debuts Leo system with dual-channel fluorescence**
- Source: Stock Titan | 20251209T113222 | Somewhat-Bullish | Relevance: 99%
-  Bio-Techne (NASDAQ: TECH) has launched its enhanced Leo System, an upgraded Simple Western platform. This system integrates chemiluminescence with dual-channel near-infrared and infrared fluorescence, significantly expanding its multiplexing capabilities for protein analysis. Key features include the ability to quantify up to 24 targets per sample, process 100 capillaries in three hours with reported 5â€“6% variability, and support 21 CFR Part 11 compliance.

**2. Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis**
- Source: Investing News Network | 20251209T120903 | Bullish | Relevance: 99%
-  Bio-Techne Corporation has launched its enhanced Leo System, powered by Simple Western Technology, which introduces dual-channel fluorescence detection alongside chemiluminescence for advanced protein analysis. This system offers expanded multiplexing capabilities, enabling researchers to quantify multiple targets simultaneously and process up to 100 capillaries within three hours. The new Leo System aims to provide unmatched precision and efficiency for clinical research and drug discovery, supporting 21 CFR Part 11 compliance.

**3. Mixed Signals from Institutional Investors Cloud Bio-Techne's Outlook ()**
- Source: Aktiencheck | 20251207T050916 | Neutral | Relevance: 97%
-  Bio-Techne (NASDAQ: TECH) is experiencing market indecision after a mixed quarterly earnings report, with institutional investors showing divergent strategies. While some major players like Select Equity Group L.P. and Norges Bank significantly increased their holdings, others like Brown Advisory Inc. trimmed their stakes. The company faces sector headwinds, including reduced biotech funding and pressure from cell therapy clients, but analysts maintain a "Moderate Buy" rating with an implied upside.

**4. Bio-Techne Announces Expanded Launch Of Next-Generation Leo System**
- Source: Nasdaq | 20251209T120903 | Somewhat-Bullish | Relevance: 96%
- Bio-Techne Corp. (TECH) has announced the expanded launch and first shipment of its next-generation Leo System, aiming to set new standards in protein analysis. The system, powered by Simple Western Technology, features dual-channel fluorescence and chemiluminescence detection, promising enhanced data throughput and efficiency for researchers. This innovation is expected to accelerate critical discoveries and streamline development timelines.

**5. Subdued Growth No Barrier To Standard BioTools Inc. (NASDAQ:LAB) With Shares Advancing 26%**
- Source: Simply Wall Street | 20251206T043424 | Somewhat-Bullish | Relevance: 55%
-  Standard BioTools Inc. (NASDAQ:LAB) has seen a 26% share price increase recently, despite a 21% loss over the last year. The company's P/S ratio is 3.3x, similar to the industry average, but revenue growth is expected to decline by 21% per year over the next three years, contrasting with industry growth. This suggests that the current P/S ratio might not be justified given the negative growth forecasts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 27.5x stretched relative to 11% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 27.5 |
| Current P/E | 30.5 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.1% to -5.9% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.90% (CS: 4) | Weak |
| RSI_14 | 45.7 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.986x | Below |
| vs SMA200 | 1.087x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $60.29
- **Stop Loss:** $56.03 (7.1% risk)
- **Target:** $64.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 117
- **Position Value:** $7,053.93
- **Portfolio %:** 7.05%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*